secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-09-24T12:10:14+00:00
Accession:  0001193125-26-400213
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo advances trispecific candidate APVO451; IND-enabling studies expected 1H2027
--------------------------------------------------------------------------------

- Optimizing several trispecific candidates for reliable, scalable manufacturing, a key step toward human testing.
- Lead candidate APVO451 to enter IND-enabling studies in 1H2027.
- Trispecifics combine three functions: recognize cancer, activate immune cells, overcome tumor defenses.
- Aptevo to present additional details at an upcoming international scientific conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526400213/0001193125-26-400213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526400213/apvo-20260924.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-400213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer